Clinical journal of oncology nursing · 2026
Correcting Vitamin D Deficiency to Prevent Paclitaxel-Induced Peripheral Neuropathy: A Practice Change Evaluation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Singh Ranju Jha, Schneider Susan M, Thompson Julie A, Khan Abir, Affronti Mary Lou
Аннотация
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a persistent problem in ambulatory oncology and is associated with low serum vitamin D levels.
OBJECTIVES: This quality improvement project evaluated a practice change at a rural community cancer center (preimplementation: N = 20; postimplementation: N = 27) aimed at mitigating CIPN associated with paclitaxel treatment in patients with breast cancer by recommending vitamin D supplementation. The key goal was to reduce CIPN incidence by at least 10%.
METHODS: A pre-/postimplementation comparison of CIPN incidence among patients with breast cancer receiving paclitaxel was used before (January 2022 to December 2023) and after (June 2024 to December 2024) a practice change recommending vitamin D supplementation.
FINDINGS: CIPN incidence decreased from 80% (n = 16 of 20) preimplementation to 67% (n = 18 of 27) postimplementation, a 13% reduction that met the 10% goal. All patients with vitamin D insufficiency (N = 11) developed CIPN.
OBJECTIVES: This quality improvement project evaluated a practice change at a rural community cancer center (preimplementation: N = 20; postimplementation: N = 27) aimed at mitigating CIPN associated with paclitaxel treatment in patients with breast cancer by recommending vitamin D supplementation. The key goal was to reduce CIPN incidence by at least 10%.
METHODS: A pre-/postimplementation comparison of CIPN incidence among patients with breast cancer receiving paclitaxel was used before (January 2022 to December 2023) and after (June 2024 to December 2024) a practice change recommending vitamin D supplementation.
FINDINGS: CIPN incidence decreased from 80% (n = 16 of 20) preimplementation to 67% (n = 18 of 27) postimplementation, a 13% reduction that met the 10% goal. All patients with vitamin D insufficiency (N = 11) developed CIPN.